{
    "clinical_study": {
        "@rank": "107482", 
        "arm_group": [
            {
                "arm_group_label": "Treatment Group (Cohort 1)", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and ciprofloxacin through Day 21."
            }, 
            {
                "arm_group_label": "Treatment Group (Cohort 2)", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and itraconazole through Day 21."
            }, 
            {
                "arm_group_label": "Treatment Group (Cohort 3)", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and rifampin through Day 24."
            }, 
            {
                "arm_group_label": "Treatment Group (Cohort 4)", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will take a single dose of lumacaftor in combination with ivacaftor on 3 occasions separated by 7 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the drug-drug interaction effects of ciprofloxacin,\n      itraconazole, and rifampin on the pharmacokinetics of lumacaftor in combination with\n      ivacaftor as well as to evaluate the potential effects of lumacaftor in combination with\n      ivacaftor on lung function."
        }, 
        "brief_title": "A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects", 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects must be between the ages of 18 and 55 years, inclusive\n\n          -  Body mass index (BMI) of 18 to 31 kg/m2, inclusive, and a total body weight >50 kg.\n\n        Exclusion Criteria:\n\n          -  History of any illness that, in the opinion of the investigator, might confound the\n             results of the study or pose an additional risk in administering study drug(s) to the\n             subject. This may include, but is not limited to, a history of relevant drug or food\n             allergies; history of cardiovascular or central nervous system disease; history or\n             presence of clinically significant pathology; or history of mental disease.\n\n          -  History of febrile illness within 5 days before the first dose.\n\n          -  History of Gilbert's syndrome\n\n          -  Abnormal renal function as defined at screening\n\n          -  Blood donation of approximately 1 pint (500 mL) within 56 days before study drug\n             administration\n\n          -  Treatment with an investigational drug within 30 days or 5 half-lives (or as\n             determined by the local requirements, whichever is longer) preceding the first dose\n             of study drug\n\n          -  Known hypersensitivity or prior adverse reaction to ciprofloxacin, or any member of\n             the quinolone class of antimicrobial agents (Cohort 1 only); itraconazole, or to any\n             of the other azoles (Cohort 2 only); rifampin, or to any of the rifamycins (Cohort 3\n             only)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768663", 
            "org_study_id": "VX12-809-009"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment Group (Cohort 1)", 
                    "Treatment Group (Cohort 2)", 
                    "Treatment Group (Cohort 3)", 
                    "Treatment Group (Cohort 4)"
                ], 
                "description": "tablet, 200mg taken every 12 hours", 
                "intervention_name": "Lumacaftor", 
                "intervention_type": "Drug", 
                "other_name": "VX-809"
            }, 
            {
                "arm_group_label": [
                    "Treatment Group (Cohort 1)", 
                    "Treatment Group (Cohort 2)", 
                    "Treatment Group (Cohort 3)", 
                    "Treatment Group (Cohort 4)"
                ], 
                "description": "tablet, 250mg taken every 12 hours", 
                "intervention_name": "Ivacaftor", 
                "intervention_type": "Drug", 
                "other_name": "VX-770"
            }, 
            {
                "arm_group_label": "Treatment Group (Cohort 1)", 
                "description": "750 mg taken every 12 hours", 
                "intervention_name": "Ciprofloxacin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment Group (Cohort 2)", 
                "description": "200mg taken once daily", 
                "intervention_name": "Itraconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment Group (Cohort 3)", 
                "description": "600mg taken once daily", 
                "intervention_name": "Rifampin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ciprofloxacin", 
                "Rifampin", 
                "Hydroxyitraconazole", 
                "Itraconazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Evansville", 
                    "country": "United States", 
                    "state": "Indiana"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Open-Label Study to Examine the Effect of Ciprofloxacin, Itraconazole, and Rifampin on the Pharmacokinetics of Lumacaftor in Combination With Ivacaftor in Healthy Adult Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Cohorts 1-3: PK parameters including Cmax, and AUC from time of dosing to time tau of lumacaftor and ivacaftor in the absence and presence of ciprofloxacin, itraconazole, and rifampin", 
                "safety_issue": "No", 
                "time_frame": "up to 24 days"
            }, 
            {
                "measure": "Cohort 4: Change in lung function from before treatment with lumacaftor/ivacaftor to after treatment with lumacaftor/ivacaftor.", 
                "safety_issue": "No", 
                "time_frame": "up to 21 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768663"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cohorts 1-4: Safety and tolerability as measured by adverse events (AEs) and changes in laboratory test values (serum chemistry, hematology, coagulation, and urinalysis), vital signs, standard 12 lead electrocardiograms (ECGs), and spirometry", 
                "safety_issue": "Yes", 
                "time_frame": "up to 31 days"
            }, 
            {
                "measure": "Cohort 4: PK parameters, including Cmax of lumacaftor/ivacaftor, and lung function", 
                "safety_issue": "No", 
                "time_frame": "16 days"
            }
        ], 
        "source": "Vertex Pharmaceuticals Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vertex Pharmaceuticals Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}